UroGen Pharma Ltd
Company Profile
Business description
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
Contact
400 Alexander Park Drive
4th Floor
PrincetonNJ08540
USAT: +1 646 768-9780
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
253
Stocks News & Analysis
stocks
Progress in UK expansion for undervalued ASX share
stocks
The sectors set to soar on government spending
stocks
Chart of the Week: How private companies are reshaping public markets
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,031.70 | 45.20 | -0.50% |
| CAC 40 | 7,930.84 | 143.39 | -1.78% |
| DAX 40 | 23,502.15 | 231.87 | -0.98% |
| Dow JONES (US) | 46,720.61 | 590.39 | -1.25% |
| FTSE 100 | 9,645.54 | 90.24 | -0.93% |
| HKSE | 26,241.83 | 244.07 | -0.92% |
| NASDAQ | 22,879.49 | 620.31 | -2.64% |
| Nikkei 225 | 50,276.37 | 607.31 | -1.19% |
| NZX 50 Index | 13,599.21 | 22.40 | 0.16% |
| S&P 500 | 6,687.98 | 32.34 | -0.48% |
| S&P/ASX 200 | 8,769.70 | 40.80 | -0.46% |
| SSE Composite Index | 3,997.56 | 10.20 | -0.25% |